Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) said on Friday that it has submitted an extension application to the European Medicines Agency (EMA) for a new subcutaneous formulation of Opdivo (nivolumab).
The application seeks approval across multiple previously approved adult solid tumour indications.
Validation by the EMA initiates the centralised review process.
Subcutaneous Opdivo offers faster administration times compared to the intravenous formulation and could improve the patient experience.
Phase 3 trial data supported the application, demonstrating non-inferiority in efficacy and safety.
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD